Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Invested Capital (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Return on Invested Capital for 6 consecutive years, with 0.01% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Invested Capital changed N/A to 0.01% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.01%, a N/A change, with the full-year FY2024 number at 0.18%, up 191.0% from a year prior.
  • Return on Invested Capital was 0.01% for Q1 2025 at Gyre Therapeutics, down from 0.09% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.11% in Q1 2023 to a low of 1.85% in Q1 2022.
  • A 4-year average of 0.45% and a median of 0.11% in 2022 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 197bps in 2023; the steepest drop was -113bps in 2023.
  • Gyre Therapeutics' Return on Invested Capital stood at 0.06% in 2022, then crashed by -1831bps to 1.19% in 2023, then soared by 108bps to 0.09% in 2024, then tumbled by -91bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Return on Invested Capital are 0.01% (Q1 2025), 0.09% (Q4 2024), and 0.91% (Q3 2024).